Protara Therapeutics, Inc. — Director's Dealing 2018

Jan 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2018-01-17

Reporting Person: Gottlieb Daniel Philip (VP Corporate Development)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-17	Stock Option (Right to Buy)	$2.85	A	110000	Acquired	2028-01-16	Common Stock, $0.001 par value (110000)	Direct

Footnotes

F1: The options were granted on January 17, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.